2nd Next Generation RNA Therapeutics Summit

Memo

The 2nd Next Generation RNA Therapeutics Summit returns as the first and only industry-dedicated forum solely focused on next generation RNA therapeutics and vaccines that are more targeted, and efficacious, with reduced off targets than first generation RNA therapies to accelerate their therapeutic and commercial potential. Expect exclusive data from KOLs on the most recent developments in circRNAs, saRNAs, eRNAs and tRNAs therapies. Join 100+ thought leaders from the likes of Pfizer, Orna Therapeutics, Laronde, Replicate Bioscience and BioNTech to stay ahead of the curve and maximize the full therapeutic potential of next generation RNA modalities to gain clinical proof concept and reach patients in need. URLs:Tickets: https://go.evvnt.com/1477463-2?pid=5569 Brochure: https://go.evvnt.com/1477463-3?pid=5569  Date and Time: On Tue, 16 May 2023 08:00 - Thu, 18 May 2023 17:10 Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Prices:Drug Developer Pricing - Conference + Workshop Day - On the Door: USD 4946.00,Drug Developer Pricing - Conference Only - On the Door: USD 2999.00,Service Provider Pricing - Conference + Workshop Day - On the Door: USD 5846.00,Service Provider Pricing - Conference Only - On the Door: USD 3599.00,Research Institutes Pricing - Conference + Workshop Day - On the Door: USD 4246.00,Research Institutes Pricing - Conference Only - On the Door: USD 2599.00 Speakers: Alex Wesselhoeft, Founder, Director of Molecular Biology, Orna Therapeutics, Anna Senczuk, Process Development Director and mRNA CMC Lead, Seqirus Inc., Anthony Saleh, Co-founder and CEO, MiRecule Inc., Bianca Lauro, Senior Scientist, Molecular Biology and mRNA Technologies, Pfizer, Brian Pickering, CEO, Chimerna Therapeutics, Burak Yilmaz, Co-Founder and President, Kernal Biologics Inc., Daniel Anderson, Professor, Chemical Engineering, MIT, Daniel Shores, Partner, Rothwell, Figg, Ernst and Manbeck, Daryl Drummond, Founder, Akagera Medicines, Dimki Patel, RNA Vaccines CMC Lead, GlaxoSmithKline Plc, Francis Poulin, Head of Process Development, Laronde, George Calin, Professor, Translational Molecular Pathology, MD Anderson Cancer Center, Gregory Fiore, CEO, Exacis Biotherapeutics, Hernando Lopez-Bertoni, Assistant Professor, Department of Neurology, The Johns Hopkins University, James Ferguson, CMO, Matinas BioPharma, John Androsavich, Global Head, RNA Emerging Science Lead, Pfizer, Justin Letendre, Scientist, Synthetic Biology, Strand Therapeutics Inc., Leslie Williams, Founder, President and CEO, hC Bioscience, Michael Mingueneau, Head of Immunology, Laronde, Michelle Werner, CEO, AlltrnaTherapeutics, Nathaniel Wang, CEO, Replicate Bioscience, Peng Yue, Co-Founder and CEO, ReviR Therapeutics, Priya Karmali, CTO, Capstan Therapeutics, Shanshan Xu, VP, External Innovations, BioNTech, Shelby Lipton, VP, mRNA and Global Marketing Lead mRNA, Pfizer, Ted Ashburn, CEO, Oncorus, Viktor Lemgart, Research Fellow, Tidal Therapeutics, Yashu Liu, Head of Bioanalytical, Laronde